ERBB2 and breast carcinoma: For example, an interesting recent report linked elevated aldo-keto reductase AKR1B10 expression in ER− and HER2+ breast cancers with an increased incidence of metastatic relapse at secondary sites that was associated with increased fatty acid utilization61.